Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration
Sign up for CuriRx’s Complimentary Lunch & Learn on November 9 at MassBio!
WILMINGTON, Mass., Sept. 21, 2021 /PRNewswire/
CuriRx, Inc., a leading contract research, development and manufacturing organization(CRDMO), announced today the launch of their new CuriLytics® platform with High-Resolution Chemistry Manufacturing and Control (CMC) analytical services. Led by CuriRx’s team of industry experts and state-of-the-art high-resolution Orbitrap mass spectrometry instrumentation, the CuriLytics™ platform provides support to developers of complex biotherapeutics.
Learn more about CuriLytics™ here.
Read the full press release here.